| Ruxolitinib. | |
| | |
MedLine Citation:
|
PMID: 22293561 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis. |
| | |
Authors:
|
Ruben A Mesa; Uma Yasothan; Peter Kirkpatrick |
Publication Detail:
|
Type: Journal Article Date: 2012-02-01 |
Journal Detail:
|
Title: Nature reviews. Drug discovery Volume: 11 ISSN: 1474-1784 ISO Abbreviation: Nat Rev Drug Discov Publication Date: 2012 |
Date Detail:
|
Created Date: 2012-02-01 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101124171 Medline TA: Nat Rev Drug Discov Country: England |
Other Details:
|
Languages: eng Pagination: 103-4 Citation Subset: IM |
Affiliation:
|
Division of Hematology & Medical Oncology, Mayo Clinic, Scottsdale, Arizona 85259, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: (Mis)treating the pharmacogenetic incidentalome.
Next Document: Targeting IAP proteins for therapeutic intervention in cancer.